Effect of Photodynamic Therapy and Anti-VEGF Therapy in the Treatment of Corneal Neovascularization : (FTIR) Study

Authors

  • Mohamed I. El Gohary  Physics Department, Biophysics Branch, Faculty of Science, Al-Azhar University(Boys), Nasr City, Cairo
  • Salwa A. Abdelkawi  Department of Vision Science, Biophysics and Laser Unit, Research Institute of Ophthalmology, Giza, Egypt
  • Aziza A. Hassan and Ayman S. El Shinawy  Ophthalmic Unit, National Institute for Laser Enhanced Science, Cairo University, Egypt

Keywords:

Corneal neovascularization, Photodynamic therapy, Rose bengal, Argon laser, Bevacizumab, Fourier transform IR.

Abstract

The aim of the present study was to compare the effect of photodynamic therapy (PDT) by using argon laser and bevacizumab (Avastin) on corneal neovascularization (CNV) in rabbits. Thirty-Nine New Zealand male rabbits aged 2.5 months and weighing 2.5 - 3kg. All rabbits’ eyes were examined by slit lamp biomicroscope before induction of corneal neovascularization. Three rabbits (N=6 eyes) were used as control, and 36 rabbits (N=72 eyes) were generally anesthetized using intramuscular Xylaject (0.2 ml/kg) and ketamine hydrochloride (0.6 ml/ kg). Benoxinate eye drops (0.4%) was used for local anesthesia. Corneal neovascularization (CNV) was induced by a three-interrupted 7.0 silk sutures at midstromal depth approximately 1 mm from the limbus. After four days' sutures were removed and slit lamp examinations were performed to determine the area of corneal neovascularization. Twelve rabbits with corneal NV were left without any treatment. photodynamic therapy group (N=12 rabbits) were generally anesthetized and rose bengal (C20H4Cl4I4O5) with a dose of 50 mg/Kg was administered by slow intravenous injection in the marginal ear vein. Argon laser (532 nm) was applied for 5 minutes with a power of 150 mW/cm2. Bevacizumab group was the last group (N=12 rabbits) were the rabbits were subjected to intravitreal injection of 25 mg / eyes. For a period of 4 weeks, three rabbits were selected and sacri?ced weekly (N = 6 eyes each) from several groups.

References

  1. Chang JH, Gabison EE, Kato T, Azar DT. 2001. Corneal neovascularization. Curr Opin Ophthalmol.12(4):242–249.
  2. Conn H, Berman M, Kenyon K, et al. 1980. Stromal vascularization prevents corneal ulceration. Invest Ophthalmol Vis Sci. 19(4):362–370.
  3. Epstein RJ, Stulting RD, Hendricks RL, Harris DM. 1987 Corneal neovascularization. Pathogenesis and inhibition. Cornea. 6(4):250–257.
  4. Dana MR, Streilein JW. 1996. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 37(12):2485–2494.
  5. Folkman J. 1995. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. ;1(1):27–31.
  6. Amano S, Rohan R, Kuroki M, et al. 1998. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 39(1):18–22.
  7. Uy HS, Chan PS, Ang RE. 2008. Topical bevacizumab and ocular surface neovascularization in patients with stevens Johnson syndrome. Cornea. ;27(1):70–73.
  8. Bahar I, Kaiserman I, McAllum P, et al. 2008. Subconjunctival bevacizumab injection for corneal neovascularization. Cornea. ;27(2):142–147.
  9. Manzano RP, Peyman GA, Khan P, et al. 2007. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) Br J Ophthalmol. ;91(6):804–807.
  10. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1(1):27–31.
  11. Amano S, Rohan R, Kuroki M, et al. Requirement for vascular endothelial growth factor in wound- and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998;39(1):18–22.
  12. Philipp W, Speicher L, Humpel C. Expression of vascular endothelial growth factor and its receptors in inflamed and vascularized human corneas. Invest Ophthalmol Vis Sci. 2000;41(9):2514–2522.
  13. Cursiefen C, Cao J, Chen L, et al. Inhibition of hemangiogenesis and lymphangiogenesis after normal-risk corneal transplantation by neutralizing VEGF promotes graft survival. Invest Ophthalmol Vis Sci.2004;45(8):2666–2673.
  14. Pieramici DJ, Rabena MD. Anti-VEGF therapy: comparison of current and future agents. Eye. 2008.
  15. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113(3):363–372. e5.
  16. Iturralde D, Spaide RF, Meyerle CB, et al. 2006 Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short-term study. Retina.;26(3):279–284.
  17. Avery RL, Pearlman J, Pieramici DJ, et al. 2006 Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology.;113(10):1695. e1–15.
  18. Iliev ME, Domig D, Wolf-Schnurrbursch U, et al. 2006 Intravitreal bevacizumab (Avastin) in the treatment of neovascular glaucoma. Am J Ophthalmol.;142(6):1054–1056.
  19. "Bevacizumab - Drugs.com". www.drugs.com. Archived from the original on 28 December 2016.
  20. "Bevacizumab Injection: MedlinePlus Drug Information". NLM.nih.gov. 28 February 2014.
  21. "Bevacizumab"2016. The American Society of Health-System Pharmacists. Archived from the original on 20 December.
  22. "WHO Model List of Essential Medicines (19th List)" . World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016.
  23. "WHO Model List of EssentialMedicines". World Health Organization. October 2013. Archived (PDF) from the original on 23 April 2014.
  24. Uy HS, Chan PS, Ang RE. 2008 Topical bevacizumab and ocular surface neovascularization in patients with stevens-johnson syndrome. Cornea.27(1):70–73.
  25. Kim TI, Kim SW, Kim S, et al. 2008 Inhibition of experimental corneal neovascularization by using subconjunctival injection of bevacizumab (Avastin) Cornea.27(3):349–352.
  26. Manzano RP, Peyman GA, Khan P, et al. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) Br J Ophthalmol. 2007;91(6):804–807.
  27. Kim SW, Ha BJ, Kim EK, et al. The effect of topical bevacizumab on corneal neovascularization.Ophthalmology. 2008;115(6):e33–e38.
  28. DeStafeno JJ, Kim T. Topical bevacizumab therapy for corneal neovascularization. Arch Ophthalmol.2007;125(6):834–836.
  29. Wayner D. D., Burton G. W., Ingold K. U., Barclay L. R., Locke S. J., The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma: Biochem. Biophys. Acta 924, 408 – 419 (1987).

International Journal of Scientific Research in Science, Engineering and Technology

Downloads

Published

2017-10-30

Issue

Volume 3, Issue 6, September-October-2017

Section

Research Articles

License

Copyright (c) IJSRSET

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

[1]
Mohamed I. El Gohary, Salwa A. Abdelkawi, Aziza A. Hassan and Ayman S. El Shinawy, " Effect of Photodynamic Therapy and Anti-VEGF Therapy in the Treatment of Corneal Neovascularization : (FTIR) Study, International Journal of Scientific Research in Science, Engineering and Technology(IJSRSET), Print ISSN : 2395-1990, Online ISSN : 2394-4099, Volume 3, Issue 6, pp.1098-1106, September-October-2017.